Darbepoetin Alfa Significantly Lowers Vascular Access Thrombosis in Dialysis Patients

Cresp logo
A randomized, prospective, open-labeled study of 24 weeks 
included stable patients on dialysis >3 months
Study Population: 139 dialysis patients
Erythropoietin-Stimulating Agent

139 dialysis patients: 72 in the Darbepoetin Alfa group and 67 in the short-acting Erythropoietin-Stimulating Agent (ESAs).

Results of Patients treated with Darbepoetin Alfa
Erythropoietin-Stimulating Agent
  • Patients treated with Darbepoetin Alfa showed a statistically significant 1.4% reduction in the incidence of vascular access thrombosis compared to 12% in Epoetin.
  • Significantly higher dose change is required in Epoetin vs Darbpoetin Alfa (1.99 vs 1.26, p<0.01).
Darbepoetin Alfa is more effective than traditional ESAs conclusion
Darbepoetin Alfa is more effective than traditional ESAs

Darbepoetin Alfa is more effective than traditional ESAs in reducing vascular access thrombosis in dialysis patients.